** Shares of healthcare company Allurion Technologies
** Company says initial data shows patients treated with its device along with low doses of Novo Nordisk's NOVOb.CO semaglutide resulted in average total body weight loss of 20.3% and lean body mass increase to 68.5%
** Company's device called Allurion Balloon occupies space in the stomach and is designed to promote satiety and reduce food consumption
** The balloon is non-surgical, swallowed and is designed to naturally empty and be eliminated about 4 months later - ALUR
** Company says all 52 patients remained adherent to the GLP-1 medication through eight months
** Additional data on the combination approach is being collected and is expected to be presented at upcoming medical meetings - company
** Stock had fallen 88.5% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.